These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35056397)

  • 1. Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer: What Is the Real Impact of Squamous Cell Carcinoma Variant on Oncological Outcomes?
    Mantica G; Chierigo F; Malinaric R; Smelzo S; Ambrosini F; Beverini M; Guano G; Caviglia A; Rigatti L; De Rose AF; Tafuri A; De Marchi D; Gaboardi F; Suardi N; Terrone C
    Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056397
    [No Abstract]   [Full Text] [Related]  

  • 2. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
    Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
    Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
    BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guérin may have clinical benefit for glandular or squamous differentiation in non-muscle invasive bladder cancer patients: retrospective multicenter study.
    Yorozuya W; Nishiyama N; Shindo T; Kyoda Y; Itoh N; Sugita S; Hasegawa T; Masumori N
    Jpn J Clin Oncol; 2018 Jul; 48(7):661-666. PubMed ID: 29733363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of transitional cell carcinoma with squamous differentiation which developed squamous cell carcinoma in situ in the clinical course].
    Sugiura S; Makiyama K; Yokomizo Y; Umemoto S; Miyoshi Y; Nakaigawa N; Ogawa T; Uemurai H; Yao M; Kubota Y; Yamanaka S
    Hinyokika Kiyo; 2006 Sep; 52(9):715-8. PubMed ID: 17040058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder.
    Hara I; Miyake H; Takechi Y; Eto H; Gotoh A; Fujisawa M; Okada H; Arakawa S; Kamidono S;
    Int J Urol; 2003 Jan; 10(1):19-24. PubMed ID: 12534921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
    Cockerill PA; Knoedler JJ; Frank I; Tarrell R; Karnes RJ
    BJU Int; 2016 Mar; 117(3):456-62. PubMed ID: 25682834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
    Huang B; Huang G; Li W; Chen L; Mao X; Chen J
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer.
    Thiel T; Ryk C; Renström-Koskela L; Steineck G; Schumacher MC; Wiklund NP; de Verdier PJ
    World J Urol; 2019 Jan; 37(1):155-163. PubMed ID: 29905887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of squamous cell carcinoma-associated antigen in grade 3 pT1 transitional cell carcinoma of the bladder and prediction of its progression and intravesical recurrence.
    Yamazaki K; Kumamoto Y; Tsukamoto T
    Cancer; 1993 Dec; 72(12):3676-84. PubMed ID: 7902777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.
    Schmidt S; Kunath F; Coles B; Draeger DL; Krabbe LM; Dersch R; Kilian S; Jensen K; Dahm P; Meerpohl JJ
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011935. PubMed ID: 31912907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thermal intravesical chemotherapy in adjuvant treatment of high risk non-muscle invasive bladder cancer.
    Efiloğlu Ö; Bayrak Ö; Turan T; Kazan HÖ; Çulpan M; Çakıcı MÇ; Erturhan S; Yıldırım A
    Arch Esp Urol; 2021 Nov; 74(9):875-882. PubMed ID: 34726624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.